+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tenosynovial Giant Cell Tumors (TSGCTS) - Epidemiology Forecast To 2028

  • ID: 4855543
  • Report
  • November 2019
  • Region: Global
  • 106 pages
  • DelveInsight
1 of 2
‘Tenosynovial Giant Cell Tumors (TSGCTs) - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Tenosynovial Giant Cell Tumors (TSGCTs) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2028

Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology

The Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Tenosynovial Giant Cell Tumors (TSGCTs) are studied through all possible division to give a better understanding of the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Segmentation

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by:
  • Diagnosed Incidence of Tenosynovial Giant Cell Tumors (TSGCTs)
  • Growth Pattern-specific Diagnosed Incidence of Tenosynovial Giant Cell Tumor (TSGCTs)
  • Gender-specific Diagnosed Incidence of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs)
  • Gender-specific Diagnosed Incidence of Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs)
  • Tumor Localization of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs)
  • Tumor Localization of Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs)
According to this research, the total diagnosed incident cases of Tenosynovial Giant Cell Tumors (TSGCTs) in the seven major markets were 13,580 by 2017. Moreover, the total diagnosed incident cases of Tenosynovial Giant Cell Tumors (TSGCTs) in the US were 7,557 cases in 2017.

Report Scope
  • The report covers the detailed overview of Tenosynovial Giant Cell Tumors (TSGCTs) explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Tenosynovial Giant Cell Tumors (TSGCTs).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type-specific cases and severity specific cases of Tenosynovial Giant Cell Tumors (TSGCTs) in the 7MM.
Key Strengths
  • 10-Year Forecast of Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology
  • 7MM Coverage
  • Total Incident Cases of Tenosynovial Giant Cell Tumors (TSGCTs)
  • Incident Cases according to segmentation
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Disease Background and Overview: Tenosynovial Giant Cell Tumors (TSGCTs)
2.1. Introduction
2.2. Classification of Tenosynovial Giant Cell Tumors (TSGCTs)
3.2.1 Pigmented Villonodular Synovitis (PVNS)
3.2.2 Conventional PVNS (Intra-Articular, Diffuse-Type Giant Cell Tumor)
3.2.3 Giant Cell Tumor of the Tendon Sheath (GCTTS)
3.3 Clinical features
3.4 Molecular biology of Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis
3.5 Etiology of Tenosynovial Giant Cell Tumor
3.6 Subdivisions of Tenosynovial Giant Cell Tumor on the basis of Cellular Division
3.6.1 Diffuse-Type Giant Cell Tumor
3.6.2 Intra-articular Giant Cell Tumor of the Tendon Sheath or Pigmented Villonodular Synovitis (PVNS)
3.6.3 Malignant TSGCT (Malignant PVNS)
3.7 Pathogenesis
3.8 Biomarkers
3.9 Diagnosis
3.9.1 Clinical Evaluation
3.9.2 Imaging features
3.10 Differential Diagnosis
3.11 TSGCT in Nutshell
3.12 Diagnosis Algorithm

3. Recognized Establishments

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Diagnosed Incident Patient Population of Tenosynovial Giant Cell Tumors (TSGCTs)

5. Country Wise-Epidemiology of TSGCTs
5.1. United States
5.1.1. Assumptions and Rationale
6.1.1 Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United States
6.1.2 Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United States
6.1.3 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United States
6.1.4 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United States
6.1.5 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United States
6.1.6 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United States
5.2. EU5 Countries
6.2.1 Assumptions and Rationale
5.3. Germany
6.3.1 Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Germany
6.3.2 Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Germany
6.3.3 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Germany
6.3.4 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Germany
6.3.5 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Germany
6.3.6 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Germany
5.4. France
6.4.1 Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in France
6.4.2 Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in France
6.4.3 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in France
6.4.4 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in France
6.4.5 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in France
6.4.6 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in France
6.5 Italy
6.5.1 Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Italy
6.5.2 Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Italy
6.5.3 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Italy
6.5.4 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Italy
6.5.5 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Italy
6.5.6 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Italy
6.6 Spain
6.6.1 Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Spain
6.6.2 Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Spain
6.6.3 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Spain
6.6.4 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Spain
6.6.5 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Spain
6.6.6 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Spain
6.7 United Kingdom
6.7.1 Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United Kingdom
6.7.2 Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United Kingdom
6.7.3 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom
6.7.4 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom
6.7.5 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United Kingdom
6.7.6 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United Kingdom
6.8 Japan
6.8.1 Assumptions and Rationale
6.8.2 Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Japan
6.8.3 Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Japan
6.8.4 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Japan
6.8.5 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Japan
6.8.6 Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Japan
6.8.7 Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Japan

7 Appendix
7.4 Report Methodology

8 Capabilities

9 Disclaimer

10 About the Publisher

List of Tables
Table 1: Localization of ALNS in the different regions of the knee joint.
Table 2: Classification and Nomenclature of Tenosynovial Giant Cell Tumors (TSGCTs)
Table 3: Tenosynovial Giant Cell Tumors (TSGCTs) Total Diagnosed Incident Population in the 7MM (2017-2028)
Table 4: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United States (2017-2028)
Table 5: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United States (2017-2028)
Table 6: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United States (2017-2028)
Table 7: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United States (2017-2028)
Table 8: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United States (2017-2028)
Table 9: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United States (2017-2028)
Table 10: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Germany (2017-2028)
Table 11: Total Cases of Locally Advanced/Metastatic Tenosynovial Giant Cell Tumors (TSGCTs) in Germany (2017-2028)
Table 12: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Germany (2017-2028)
Table 13: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Germany (2017-2028)
Table 14: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Germany (2017-2028)
Table 15: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Germany (2017-2028)
Table 16: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in France (2017-2028)
Table 17: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in France (2017-2028)
Table 18: Tenosynovial Giant Cell Tumors (TSGCTs) Severity-specific Diagnosed Incident Population in France (2017-2028)
Table 19: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in France (2017-2028)
Table 20: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in France (2017-2028)
Table 21: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in France (2017-2028)
Table 22: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Italy (2017-2028)
Table 23: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Italy (2017-2028)
Table 24: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Italy (2017-2028)
Table 25: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Italy (2017-2028)
Table 26: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Italy (2017-2028)
Table 27: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Italy (2017-2028)
Table 28: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Spain (2017-2028)
Table 29: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Spain (2017-2028)
Table 30: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Spain (2017-2028)
Table 31: Diffuse Tenosynovial Giant Cell Tumors (TSGCTs) Gender-specific Diagnosed Incidence in Spain (2017-2028)
Table 32: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Spain (2017-2028)
Table 33: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Spain (2017-2028)
Table 34: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United Kingdom (2017-2028)
Table 35: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United Kingdom (2017-2028)
Table 36: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom (2017-2028)
Table 37: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom (2017-2028)
Table 38: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United Kingdom (2017-2028)
Table 39: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United Kingdom (2017-2028)
Table 40: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Japan (2017-2028)
Table 41: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Japan (2017-2028)
Table 42: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Japan (2017-2028)
Table 43: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Japan (2017-2028)
Table 44: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Japan (2017-2028)
Table 45: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Japan (2017-2028)

List of Figures
Figure 1: Illustration shows a giant cell tumor at the lower end of the thighbone and is formed by the fusion of several cells, giant cells show multiple nuclei when viewed under a microscope.
Figure 2: Localization of ALNS (articular Localized Pigmented Villonodular) form in the different regions of the knee joint.
Figure 3: Molecular pathogenesis of tenosynovial giant cell tumor/pigmented villonodular synovitis.
Figure 4: Classification of Tenosynovial GCTs
Figure 5: Classification of tenosynovial GCTs. GCT, giant cell tumor; PVNS, pigmented villonodular synovitis
Figure 6: Tenosynovial Giant Cell Tumors (TSGCTs) Total Diagnosed Incident Patient Population in the 7MM (2017-2028)
Figure 7: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United States (2017-2028)
Figure 8: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United States (2017-2028)
Figure 9: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United States (2017-2028)
Figure 10: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United States (2017-2028)
Figure 11: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United States (2017-2028)
Figure 12: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United States (2017-2028)
Figure 13: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Germany (2017-2028)
Figure 14: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Germany (2017-2028)
Figure 15: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Germany (2017-2028)
Figure 16: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Germany (2017-2028)
Figure 17: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Germany (2017-2028)
Figure 18: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Germany (2017-2028)
Figure 19: Diagnosed Incidence of Tenosynovial Giant Cell Tumor (TSGCTs) in France (2017-2028)
Figure 20: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in France (2017-2028)
Figure 21: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in France (2017-2028)
Figure 22: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in France (2017-2028)
Figure 23: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in France (2017-2028)
Figure 24: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in France (2017-2028)
Figure 25: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Italy (2017-2028)
Figure 26: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Italy (2017-2028)
Figure 27: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Italy (2017-2028)
Figure 28: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Italy (2017-2028)
Figure 29: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Italy (2017-2028)
Figure 30: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Italy (2017-2028)
Figure 31: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Spain (2017-2028)
Figure 32: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Spain (2017-2028)
Figure 33: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Spain (2017-2028)
Figure 34: Diffuse Tenosynovial Giant Cell Tumors (TSGCTs) Gender-specific Diagnosed Incidence in Spain (2017-2028)
Figure 35: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Spain (2017-2028)
Figure 36: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Spain (2017-2028)
Figure 37: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United Kingdom (2017-2028)
Figure 38: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United Kingdom (2017-2028)
Figure 39: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom (2017-2028)
Figure 40: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom (2017-2028)
Figure 41: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United Kingdom (2017-2028)
Figure 42: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United Kingdom (2017-2028)
Figure 43: Diagnosed Incidence of Tenosynovial Giant Cell Tumor (TSGCTs) in Japan (2017-2028)
Figure 44: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Japan (2017-2028)
Figure 45: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Japan (2017-2028)
Figure 46: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Japan (2017-2028)
Figure 47: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Japan (2017-2028)
Figure 48: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Japan (2017-2028)
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll